Short-term effects of β2-AR blocker ICI 118,551 on sarcoplasmic reticulum SERCA2a and cardiac function of rats with heart failure

Gong,Haibin; Li,Yanfei; Wang,Lei; Lv,Qian; Wang,Xiuli

doi:10.3892/etm.2016.3450

Short-term effects of β2-AR blocker ICI 118,551 on sarcoplasmic reticulum SERCA2a and cardiac function of rats with heart failure

Authors:
- Haibin Gong
- Yanfei Li
- Lei Wang
- Qian Lv
- Xiuli Wang
View Affiliations

Affiliations: Department of Cardiology, Xuzhou Central Hospital, Xuzhou Cardiovascular Disease Institute, Xuzhou, Jiangsu 221009, P.R. China
Published online on: June 13, 2016 https://doi.org/10.3892/etm.2016.3450
Pages: 1355-1362
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The study was conducted to examine the effects of ICI 118,551 on the systolic function of cardiac muscle cells of rats in heart failure and determine the molecular mechanism of selective β2-adrenergic receptor (β2-AR) antagonist on these cells. The chronic heart failure model for rats was prepared through abdominal aortic constriction and separate cardiac muscle cells using the collagenase digestion method. The rats were then divided into Sham, HF and HF+ICI 50 nM goups and cultivated for 48 h. β2-AR, Gi/Gs and sarcoplasmic reticulum Ca2+‑ATPase (SERCA2a) protein expression levels in the cardiac muscle cells were evaluated by western blotting and changes in the systolic function of cardiac muscle cells based on the boundary detection system of contraction dynamics for individual cells was measured. The results showed that compared with the Sham group, the survival rate, percentage of basic contraction and maximum contraction amplitude percentage of cardiac muscle cells with heart failure decreased, Gi protein expression increased while Gs and SERCA2a protein expression decreased. Compared with the HF group, the maximum contraction amplitude percentage of cardiac muscle cells in group HF+ICI 50 nM decreased, the Gi protein expression level increased while the SERCA2a protein expression level decreased. Following the stimulation of Ca2+ and ISO, the maximum contraction amplitude percentage of cardiac muscle cells in the HF+ICI 50 nM group was lower than that in group HF. This indicated that ICI 118,551 has negative inotropic effects on cardiac muscle cells with heart failure, which may be related to Gi protein. Systolic function of cardiac muscle cells with heart failure can therefore be reduced by increasing Gi protein expression and lowering SERCA2a protein expression.

View Figures

View References

1	Dzimiri N: Regulation of β-adrenoceptor signaling in cardiac function and disease. Pharmacol Rev. 51:465–501. 1999.PubMed/NCBI
2	Xiao RP and Lakatta EG: Beta 1-adrenoceptor stimulation and beta 2-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca²⁺, and Ca²⁺ current in single rat ventricular cells. Circ Res. 73:286–300. 1993. View Article : Google Scholar : PubMed/NCBI
3	Zheng M, Han QD and Xiao RP: Distinct β-adrenergic receptor subtype signaling in the heart and their pathophysiological relevance. Sheng Li Xue Bao. 56:1–15. 2004.PubMed/NCBI
4	Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P and Jamieson S: Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 59:297–309. 1986. View Article : Google Scholar : PubMed/NCBI
5	Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homcy CJ, Vatner SF and Vatner DE: Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest. 91:907–914. 1993. View Article : Google Scholar : PubMed/NCBI
6	Lv Z and Huang R: Common issues of neuroendocrine antagonist in treatment of chronic cardiac failure. Chin J Cardiol. 33:293–296. 2005.(In Chinese).
7	Aoyagi T, Yonekura K, Eto Y, Matsumoto A, Yokoyama I, Sugiura S, Momomura S, Hirata Y, Baker DL and Periasamy M: The sarcoplasmic reticulum Ca²⁺-ATPase (SERCA2) gene promoter activity is decreased in response to severe left ventricular pressure-overload hypertrophy in rat hearts. J Mol Cell Cardiol. 31:919–926. 1999. View Article : Google Scholar : PubMed/NCBI
8	Kögler H, Hartmann O, Leineweber K, van Nguyen P, Schott P, Brodde OE and Hasenfuss G: Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. Circ Res. 93:230–237. 2003. View Article : Google Scholar : PubMed/NCBI
9	Dash R, Frank KF, Carr AN, Moravec CS and Kranias EG: Gender influences on sarcoplasmic reticulum Ca²⁺-handling in failing human myocardium. J Mol Cell Cardiol. 33:1345–1353. 2001. View Article : Google Scholar : PubMed/NCBI
10	Spragg DD, Leclercq C, Loghmani M, Faris OP, Tunin RS, DiSilvestre D, McVeigh ER, Tomaselli GF and Kass DA: Regional alterations in protein expression in the dyssynchronous failing heart. Circulation. 108:929–932. 2003. View Article : Google Scholar : PubMed/NCBI
11	Wei J, Liu HC, Lee FY, Lee MS, Huang CY, Pan HP and Lin CI: Role of the sarcoplasmic reticulum in altered action potential and contraction of myopathic human and hamster ventricle. Clin Exp Pharmacol Physiol. 30:232–241. 2003. View Article : Google Scholar : PubMed/NCBI
12	Van de Caetsbeek I, Raeymaekers L, Wuytack F and Vangheluwe P: Factors controlling the activity of the SERCA2a pump in the normal and failing heart. Biofactors. 35:484–499. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Nakayama H, Otsu K, Suzuki K, Tada M, Hori M, et al: Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix. J Hypertens. 21:1737–1745. 2003. View Article : Google Scholar : PubMed/NCBI
14	Sabbah HN, Sharov VG, Gupta RC, Mishra S, Rastogi S, Undrovinas AI, Chaudhry PA, Todor A, Mishima T, Tanhehco EJ, et al: Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res. 93:1095–1101. 2003. View Article : Google Scholar : PubMed/NCBI
15	Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology: Guidelines for the diagnosis and management of chronic heart failure. Chin J Cardiol. 35:1076–1095. 2007.
16	Brixius K, Frank KF, Bölck B, Hoyer F and Schwinger RH: Reverse remodeling of the intracellular Ca(2+)-homeostasis: new concepts of pathophysiology and therapy of heart failure. Wien Med Wochenschr. 156:209–215. 2006.(In German). View Article : Google Scholar : PubMed/NCBI
17	Gong H, Adamson DL, Ranu HK, Koch WJ, Heubach JF, Ravens U, Zolk O and Harding SE: The effect of Gi-protein inactivation on basal, and beta(1)- and beta(2)AR-stimulated contraction of myocytes from transgenic mice overexpressing the beta(2)-adrenoceptor. Br J Pharmacol. 131:594–600. 2000. View Article : Google Scholar : PubMed/NCBI
18	Hamdani N, de Waard M, Messer AE, Boontje NM, Kooij V, van Dijk S, Versteilen A, Lamberts R, Merkus D, Dos Remedios C, et al: Myofilament dysfunction in cardiac disease from mice to men. J Muscle Res Cell Motil. 29:189–201. 2008. View Article : Google Scholar : PubMed/NCBI
19	Lohse MJ, Engelhardt S and Eschenhagen T: What is the role of beta-adrenergic signaling in heart failure? Circ Res. 93:896–906. 2003. View Article : Google Scholar : PubMed/NCBI
20	Lee DI, Vahebi S, Tocchetti CG, Barouch LA, Solaro RJ, Takimoto E and Kass DA: PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol. 105:337–347. 2010. View Article : Google Scholar : PubMed/NCBI
21	Tóth A, Kiss L, Varró A and Nánási PP: Potential therapeutic effects of Na⁺/Ca²⁺ exchanger inhibition in cardiac diseases. Curr Med Chem. 16:3294–3321. 2009. View Article : Google Scholar : PubMed/NCBI
22	Vinge LE, Raake PW and Koch WJ: Gene therapy in heart failure. Circ Res. 102:1458–1470. 2008. View Article : Google Scholar : PubMed/NCBI
23	Sun H, Zhou F, Wang Y, Zhang Y, Chang A and Chen Q: Effects of beta-adrenoceptors overexpression on cell survival are mediated by Bax/Bcl-2 pathway in rat cardiac myocytes. Pharmacology. 78:98–104. 2006. View Article : Google Scholar : PubMed/NCBI